Ebola vaccine to begin human trials

11 November 2021

The University of Oxford have begun recruiting for a Phase I trial to test an Ebola vaccine in human volunteers – with the first vaccinations taking place today (Thursday, 11 November).

The study will assess the immune response and safety of the new vaccine against the Zaire and Sudan species of Ebola.

A planned sample of 26 participants – who must be assessed as healthy and aged 18 to 55 – will all receive one dose of the ChAdOx1 biEBOV vaccine at the University. Following vaccination, participants will be monitored through several visits over a six-month period, with results expected in the second quarter of 2022.

The vaccine is based on the ChAdOx1 virus, a weakened version of a common cold virus (adenovirus) that has been genetically modified so that it is impossible for it to replicate in humans. This vector has been previously used successfully in the ChAdOx1 nCoV-19 vaccine – or the Oxford-AstraZeneca vaccine.

Professor Teresa Lambe OBE, Associate Professor at the Jenner Institute and Lead Scientific Investigator, University of Oxford, said: ‘The 2014-2016 Ebola virus disease outbreak in West Africa cost more than 11,000 lives and had a catastrophic effect on healthcare systems.
‘Sporadic Ebolavirus outbreaks still occur in affected countries, putting the lives of individuals – especially frontline health workers – at risk. We need more vaccines to tackle this devastating disease.’

Dr Daniel Jenkin, Principal Investigator of the trial at the Jenner Institute, University of Oxford, said: ‘Recent advances have led to the approval of vaccines against one of the viruses that causes Ebola virus disease. However, this disease can be caused by several different species of virus and each of these may require a targeted immune response to offer protection.
‘We have designed our new vaccine to target the two species of virus that have caused nearly all Ebolavirus outbreaks and deaths, and now look forward to testing this in phase I clinical trials.’

Dr Paola Cicconi, Chief Investigator of the trial at the Jenner Institute, University of Oxford, said: ‘The need for a multivalent vaccine, approved for use against multiple Ebolavirus species, remains unmet. Experience with ChAdOx1 nCoV-19 (Oxford-AstraZeneca COVID-19 vaccine) has shown the vaccine can be rapidly manufactured at high volume for low cost, with storage conditions amenable to use in the developing world.
‘This study will provide valuable data on the safety and immunological aspects of a novel multivalent Ebolavirus ChAdOx1 vaccine.’

Volunteers interested in enrolling on the study can do so online.

A further trial for the vaccine is planned to commence in Tanzania by the end of 2021.

Notes to editors: 

For further information or to request an interview with the researchers, please contact: [email protected] or call 01865 280528.

Trial link – https://www.jenner.ac.uk/volunteer/recruiting-trials/ebola-virus-vaccine-study-ebl07

About the University of Oxford
Oxford University has been placed number 1 in the Times Higher Education World University Rankings for the sixth year running, and at the heart of this success is our ground-breaking research and innovation.
Oxford is world-famous for research excellence and home to some of the most talented people from across the globe. Our work helps the lives of millions, solving real-world problems through a huge network of partnerships and collaborations. The breadth and interdisciplinary nature of our research sparks imaginative and inventive insights and solutions.
Through its research commercialisation arm, Oxford University Innovation, Oxford is the highest university patent filer in the UK and is ranked first in the UK for university spinouts, having created more than 200 new companies since 1988. Over a third of these companies have been created in the past three years.